Koers Coeptis Therapeutics, Inc. OTC Markets
Aandelen
COEP
US19207C1045
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 13,53 mln. 12,59 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -26 mln. -24,19 mln. | Nettowinst (verlies) 2025 * | -35 mln. -32,56 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,49
x | K/w-verhouding 2025 * |
-0,43
x | Werknemers | 6 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 67,46% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 28-10-22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 17-05-23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28-10-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 62 | 28-10-22 | |
Director/Board Member | 55 | 28-10-22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 28-10-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,43% | 690 mld. | |
+26,43% | 546 mld. | |
-5,12% | 358 mld. | |
+19,59% | 323 mld. | |
+4,89% | 287 mld. | |
+14,32% | 235 mld. | |
+5,79% | 199 mld. | |
-9,49% | 195 mld. | |
+4,26% | 161 mld. |